Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 2
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean xinglong zheng (41 results)?
Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma.
Li C, Zheng X, Li P, Wang H, Hu J, Wu L, Wang Z, Guo H, Wu F, Zhong W, Zhou C, Chu Q, Zhao J, Zheng X, Xiao W, Zhu W, Zhang L, Li Q, Jiang K, Miao Q, Wu B, Xu Y, Wu S, Wang H, Yang S, Li Y, Xia X, Yi X, Huang C, Zhu B, Lin G. Li C, et al. Among authors: zheng x. Front Immunol. 2022 Aug 12;13:944812. doi: 10.3389/fimmu.2022.944812. eCollection 2022. Front Immunol. 2022. PMID: 36032124 Free PMC article.
CD8+ T cell/cancer-associated fibroblast ratio stratifies prognostic and predictive responses to immunotherapy across multiple cancer types.
Zheng X, Jiang K, Xiao W, Zeng D, Peng W, Bai J, Chen X, Li P, Zhang L, Zheng X, Miao Q, Wang H, Wu S, Xu Y, Xu H, Li C, Li L, Gao X, Zheng S, Li J, Wang D, Zhou Z, Xia X, Yang S, Li Y, Cui Z, Zhang Q, Chen L, Lin X, Lin G. Zheng X, et al. Front Immunol. 2022 Nov 9;13:974265. doi: 10.3389/fimmu.2022.974265. eCollection 2022. Front Immunol. 2022. PMID: 36439099 Free PMC article.
Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer.
Xu Y, Yan J, Zhou C, Wu L, Wang H, Zhao J, Zhou M, Wang J, Zheng X, Zhang L, Jiang K, Zheng X, Miao Q, Wu S, Zou Z, Lian R, He Y, Chen R, Yang S, Li Y, Chen S, Lin G. Xu Y, et al. Among authors: zheng x. Eur J Cancer. 2023 Jul;188:81-89. doi: 10.1016/j.ejca.2023.04.009. Epub 2023 Apr 20. Eur J Cancer. 2023. PMID: 37201385
Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study.
Zheng X, Zhang L, Wu L, Zhao J, Sun J, Fang Y, Zhou J, Chu Q, Shen Y, Yang Z, Chen L, Huang M, Lin X, Liu Z, Shen P, Wang Z, Wang X, Wang H, Han Z, Liu A, Zhang H, Ye F, Gao W, Wu F, Song Z, Chen S, Zhou C, Wang Q, Xu C, Huang D, Zheng X, Miao Q, Jiang K, Xu Y, Wu S, Wang H, Zhang Q, Yang S, Li Y, Chen S, Lin G. Zheng X, et al. BMC Cancer. 2023 Dec 16;23(1):1244. doi: 10.1186/s12885-023-11737-x. BMC Cancer. 2023. PMID: 38104105 Free PMC article.
Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis.
Hong Y, Miao Q, Zheng X, Xu Y, Huang Y, Chen S, Huang Z, Xu H, Jiang K, Zhong Q, Zhang L, Zheng X, Zeng H, Yang S, Li Y, Li S, Zhuang W, Lin G. Hong Y, et al. Among authors: zheng x. J Neurooncol. 2023 Nov;165(2):301-312. doi: 10.1007/s11060-023-04483-4. Epub 2023 Nov 23. J Neurooncol. 2023. PMID: 37995007
12 results